دورية أكاديمية
أعرض في EDS

Biomarker for cardiorenal syndrome risk in patients with liver cirrhosis and type 2 diabetes in Saudi Arabia.

التفاصيل البيبلوغرافية
العنوان: Biomarker for cardiorenal syndrome risk in patients with liver cirrhosis and type 2 diabetes in Saudi Arabia.
المؤلفون: Mohammedsaeed W; From the Department of Clinical Laboratory Sciences (Mohammedsaeed), Faculty of Applied Medical Science,Taibah University; and from the Department of Endocrinology and Diabetes Center(Alghamdi), King Fahad Hospital, Al Madina Al Munawara, Kingdom of Saudi Arabia., Alghamdi ZJ; From the Department of Clinical Laboratory Sciences (Mohammedsaeed), Faculty of Applied Medical Science,Taibah University; and from the Department of Endocrinology and Diabetes Center(Alghamdi), King Fahad Hospital, Al Madina Al Munawara, Kingdom of Saudi Arabia.
المصدر: Saudi medical journal [Saudi Med J] 2024 Jul; Vol. 45 (7), pp. 675-684.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Medical Services Department, Saudi Arabian Armed Forces, Ministry Of Defence And Aviation Country of Publication: Saudi Arabia NLM ID: 7909441 Publication Model: Print Cited Medium: Internet ISSN: 1658-3175 (Electronic) Linking ISSN: 03795284 NLM ISO Abbreviation: Saudi Med J Subsets: MEDLINE
أسماء مطبوعة: Publication: Riyadh : Medical Services Department, Saudi Arabian Armed Forces, Ministry Of Defence And Aviation
Original Publication: Riyadh, Saudi Arabia, Riyadh Al-Kharj Hospital Programme.
مواضيع طبية MeSH: Diabetes Mellitus, Type 2*/complications , Diabetes Mellitus, Type 2*/epidemiology , Liver Cirrhosis*/complications , Liver Cirrhosis*/epidemiology , Biomarkers*/blood , Cardio-Renal Syndrome*/epidemiology , Cardio-Renal Syndrome*/etiology, Humans ; Female ; Male ; Saudi Arabia/epidemiology ; Middle Aged ; Risk Factors ; Retrospective Studies ; Aged ; Adult ; Body Mass Index ; C-Reactive Protein/analysis ; C-Reactive Protein/metabolism ; Glomerular Filtration Rate ; Glycated Hemoglobin/analysis ; Creatinine/blood
مستخلص: Objectives: To evaluate the correlation between different attributes, levels of biomarkers, and the probability of developing cardiorenal syndrome (CRS) in patients who have been diagnosed with type 2 diabetes mellitus (T2DM) and liver cirrhosis (LC). The hypothesis suggests that liver illness may be linked to renal impairment, cardiac dysfunction, and the development of cardiorenal syndrome METHODS: The current study retrospectively assessed the medical records of patients who had LC and T2DM diagnoses and were hospitalized at Al Madina Al Munwara hospitals in 2022 and 2023.
Results: This research investigated T2DM patients with physician-confirmed to have LC. Poor glycemic control is indicated by high blood glucose and glycated hemoglobin (HbA1c) readings in research participants. High blood pressure, atherogenic plasma indicator (AIP), and obesity plagued most of these individuals. High creatinine, moderate estimated Glomerular Filtration Rate (eGFR) decline, and a modest urinary albumin-to-creatinine (UACR) rise were the most prevalent variables in LC and T2DM patients. Cardiorenal syndrome risk factors, including elevated blood pressure, triglyceride levels, body mass index (BMI), and high-sensitivity C-reactive protein (hs-CRP) concentrations, were identified through logistic regression. It has been demonstrated that the prevalence of these risk factors increases with age; women may be at a greater risk for developing CRS. Specific biomarker evaluations classified 108 (22.6%) LC and T2DM patients at high risk for chronic kidney disease (CKD), 100 (20%) at risk for cardiovascular disease (CVD), and 91 (18.2%) at risk for CRS.
Conclusion: The current assessment included 500 patients with T2DM and LC. The risk factors for CRS identified in this study included elevated cholesterol and triglyceride levels, high BMI, and elevated blood pressure, with age being a significant factor, particularly in female patients. Early identification of these characteristics in patients with LC and T2DM could aid in mitigating the progression of chronic illnesses and their associated complications.
(Copyright: © Saudi Medical Journal.)
References: Lancet. 2004 Jan 10;363(9403):157-63. (PMID: 14726171)
Eur Heart J. 2005 Jan;26(1):11-7. (PMID: 15615794)
Indian Heart J. 2017 Mar - Apr;69(2):255-265. (PMID: 28460776)
Annu Rev Physiol. 2021 Feb 10;83:39-58. (PMID: 33074771)
Kidney Dis (Basel). 2017 Jan;2(4):151-163. (PMID: 28232932)
J Cell Mol Med. 2010 Sep;14(9):2223-34. (PMID: 20716126)
PLoS One. 2014 Dec 26;9(12):e115403. (PMID: 25541989)
Diabetes Care. 2004 Aug;27(8):1879-84. (PMID: 15277411)
Circ Heart Fail. 2011 Mar;4(2):138-44. (PMID: 21216838)
Kidney Blood Press Res. 2016;41(5):672-679. (PMID: 27676190)
Ann Intern Med. 2005 Nov 15;143(10):722-8. (PMID: 16287793)
J Am Coll Cardiol. 2009 Feb 17;53(7):582-588. (PMID: 19215832)
Heart Fail Rev. 2022 Nov;27(6):2137-2153. (PMID: 35133552)
Eur Heart J. 2010 Mar;31(6):703-11. (PMID: 20037146)
Kidney Int Suppl (2011). 2013 Jan;3(1):5-14. (PMID: 25598998)
J Am Coll Cardiol. 2013 Aug 6;62(6):485-95. (PMID: 23747781)
Hepatology. 2013 Apr;57(4):1357-65. (PMID: 23175136)
Eur Heart J. 2010 Nov;31(22):2791-8. (PMID: 20801926)
Heart. 2010 Aug;96(16):1297-302. (PMID: 20659949)
Physiol Rev. 2015 Apr;95(2):405-511. (PMID: 25834230)
Diabetes Obes Metab. 2020 Feb;22(2):243-253. (PMID: 31602755)
Mediators Inflamm. 2016;2016:5613056. (PMID: 27340342)
Gut. 2003 Jun;52(6):879-85. (PMID: 12740346)
Cochrane Database Syst Rev. 2017 Jun 08;6:CD010137. (PMID: 28594069)
Can Fam Physician. 2013 Nov;59(11):1169-80. (PMID: 24235189)
Hypertension. 2018 Jun;71(6):e13-e115. (PMID: 29133356)
Eur Heart J. 2015 Jun 14;36(23):1437-44. (PMID: 25838436)
Int J Mol Sci. 2020 Sep 08;21(18):. (PMID: 32911600)
Nat Rev Nephrol. 2016 Oct;12(10):610-23. (PMID: 27573728)
Nephron. 1976;16(1):31-41. (PMID: 1244564)
Cleve Clin J Med. 2018 Mar;85(3):231-239. (PMID: 29522391)
N Engl J Med. 2002 Aug 1;347(5):305-13. (PMID: 12151467)
J Gastroenterol. 2014 Nov;49(11):1477-84. (PMID: 24277052)
Nat Rev Nephrol. 2020 Jan;16(1):51-64. (PMID: 31527790)
Surg Obes Relat Dis. 2009 Jan-Feb;5(1):20-6. (PMID: 18951068)
J Hypertens. 2022 Aug 1;40(8):1530-1536. (PMID: 35792492)
J Am Coll Cardiol. 2012 Sep 18;60(12):1031-42. (PMID: 22840531)
Diabetol Metab Syndr. 2023 Mar 1;15(1):32. (PMID: 36855144)
Drugs. 1990;39 Suppl 4:10-21; discussion 22-4. (PMID: 2354670)
Am J Kidney Dis. 2002 Feb;39(2 Suppl 1):S1-266. (PMID: 11904577)
Cardiovasc Diabetol. 2022 Jun 10;21(1):104. (PMID: 35689214)
Nephron. 1999;82(3):246-53. (PMID: 10395997)
Circulation. 2009 Jun 23;119(24):3070-7. (PMID: 19506115)
Int J Mol Sci. 2023 Mar 07;24(6):. (PMID: 36982164)
فهرسة مساهمة: Keywords: Saudi; biomarkers; cardiorenal; liver cirrhosis; syndrome
المشرفين على المادة: 0 (Biomarkers)
9007-41-4 (C-Reactive Protein)
0 (Glycated Hemoglobin)
AYI8EX34EU (Creatinine)
تواريخ الأحداث: Date Created: 20240702 Date Completed: 20240702 Latest Revision: 20240714
رمز التحديث: 20240714
مُعرف محوري في PubMed: PMC11237275
DOI: 10.15537/smj.2024.45.7.20240156
PMID: 38955454
قاعدة البيانات: MEDLINE
الوصف
تدمد:1658-3175
DOI:10.15537/smj.2024.45.7.20240156